Coverage
Filings
| Filing | Date |
|---|---|
| Result of AGM | 12 Mar 2008 |
| Result of AGM | 12 Mar 2008 |
| Treasury Stock | 10 Mar 2008 |
| Treasury Stock | 3 Mar 2008 |
| Treasury Stock | 3 Mar 2008 |
| Treasury Stock | 25 Feb 2008 |
| Notice of AGM | 20 Feb 2008 |
| Formal Notice | 18 Feb 2008 |
| Director/PDMR Shareholding |
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 13 Feb 2008 |
| Director/PDMR Shareholding | 11 Feb 2008 |
| Treasury Stock | 11 Feb 2008 |
| Director/PDMR Shareholding | 6 Feb 2008 |